Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise Total d...
How does this partnership with Merck KGaA compare to similar biotech‑big‑pharma collaborations in the neurology space in terms of valuation multiples and upside potential?
What are the key timelines and success criteria for the RNA‑targeting small‑molecule program, and how likely are the milestones to be met?
How will the $2 billion‑plus deal valuation and milestone structure affect Skyhawk’s cash flow and potential dilution?
8 days ago